 | |
| Combination of | |
|---|---|
| Dihydroergocristine | Ergot alkaloid |
| Dihydroergocornine | Ergot alkaloid |
| alpha-Dihydroergocryptine | Ergot alkaloid |
| beta-Dihydroergocryptine | Ergot alkaloid |
| Clinical data | |
| Other names | Co-dergocrine, dihydroergotoxine |
| Pregnancy category |
|
| Routes of administration | Oral, parenteral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 25% |
| Protein binding | 98–99% |
| Metabolism | 50% |
| Elimination half-life | 3.5 hours |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.158.718 |
  (what is this?) (verify) | |
Ergoloid mesylates (USAN), co-dergocrine mesilate (BAN) or dihydroergotoxine mesylate, trade name Hydergine, is a mixture of the methanesulfonate salts of three dihydrogenated ergot alkaloids (dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine).
It was developed by Albert Hofmann (the discoverer of LSD) for Sandoz (now part of Novartis).